|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-9-1
|
|
pubmed:abstractText |
Systemic anti-VEGF therapy with bevacizumab was effective in neovascular AMD in the SANA study. Intravitreal bevacizumab has the advantage that a high concentration can be achieved in the eye with a low dose. First clinical studies showed a good therapeutic effect.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1439-3999
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
225
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
818-24
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18759214-Adult,
pubmed-meshheading:18759214-Angiogenesis Inhibitors,
pubmed-meshheading:18759214-Antibodies, Monoclonal,
pubmed-meshheading:18759214-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18759214-Choroidal Neovascularization,
pubmed-meshheading:18759214-Exudates and Transudates,
pubmed-meshheading:18759214-Female,
pubmed-meshheading:18759214-Humans,
pubmed-meshheading:18759214-Injections,
pubmed-meshheading:18759214-Macular Degeneration,
pubmed-meshheading:18759214-Male,
pubmed-meshheading:18759214-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
[Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV)].
|
|
pubmed:affiliation |
Augenklinik, Klinikum rechts der Isar der TU München. M.Maier@lrz.tum.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract
|
